請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45786
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高純琇(Churn-Shiouh Gau) | |
dc.contributor.author | Yi-Tzu Cho | en |
dc.contributor.author | 卓怡慈 | zh_TW |
dc.date.accessioned | 2021-06-15T04:46:07Z | - |
dc.date.available | 2011-09-13 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-05 | |
dc.identifier.citation | 1. Jones P, Buckley P. Schizophrenia. London: Mosby; 2006.
2. Association AP. Schizophrenia and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000:297-319. 3. Crismon ML, Argo TR, Buckley PF. Schizophrenia. In: Dipiro JT, Talbert RL, Lee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 7 ed. New York: McGraw-Hill; 2008:1099-122. 4. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56. 5. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-62. 6. M DEH, Schreurs V, Vancampfort D, R VANW. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22. 7. Chien IC, Hsu JH, Lin CH, Bih SH, Chou YJ, Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 2009;111:17-22. 8. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601. 9. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607-18; quiz 590, 760-1. 10. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35 Suppl:S67-73. 11. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-8. 12. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129-34. 13. Hugenholtz GW, Heerdink ER, van Staa TP, Nolen WA, Egberts AC. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005;37:864-70. 14. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009;20:1499-506. 15. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008;22:46-55. 16. Hafner H, an der Heiden W, Behrens S, et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 1998;24:99-113. 17. McDonald C, Murphy KC. The new genetics of schizophrenia. Psychiatr Clin North Am 2003;26:41-63. 18. Brown AS, Susser ES. In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 2002;8:51-7. 19. McNeil TF, Cantor-Graae E, Ismail B. Obstetric complications and congenital malformation in schizophrenia. Brain Res Brain Res Rev 2000;31:166-78. 20. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9. 21. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38. 22. Krystal JH, Perry EB, Jr., Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62:985-94. 23. Carey RJ, Pinheiro-Carrera M, Dai H, Tomaz C, Huston JP. L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol Psychiatry 1995;38:669-76. 24. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44. 25. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997;23:437-58. 26. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004;4:53-7. 27. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003;26:85-102. 28. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409. 29. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122 ( Pt 4):593-624. 30. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006;12:1016-22. 31. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 1997;154:1-63. 32. Breier A, Berg PH. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biol Psychiatry 1999;46:361-4. 33. Appelbaum PS, Robbins PC, Roth LH. Dimensional approach to delusions: comparison across types and diagnoses. Am J Psychiatry 1999;156:1938-43. 34. Kitamura T, Okazaki Y, Fujinawa A, Takayanagi I, Kasahara Y. Dimensions of schizophrenic positive symptoms: an exploratory factor analysis investigation. Eur Arch Psychiatry Clin Neurosci 1998;248:130-5. 35. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982;39:784-8. 36. Hafner H, Maurer K. Are there two types of schizophrenia? True onset and sequence of positive and negative symptoms prior to first admission. In: Marneros A, Andreason NC, Tsuang MT, eds. Negative Versus Positive Schizophrenia. Berlin: Springer-Verlag; 1991:134. 37. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-36. 38. Marder SR, Wirshing WC, Mintz J, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996;153:1585-92. 39. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-24. 40. Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM. Schizophrenia and the myth of intellectual decline. Am J Psychiatry 1997;154:635-9. 41. Seidman LJ, Buka SL, Goldstein JM, Tsuang MT. Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. J Clin Exp Neuropsychol 2006;28:225-42. 42. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008;165:579-87. 43. Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997;54:2461-77. 44. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry 1990;41:1238-41. 45. Crismon ML. Psychotropic drugs in the elderly: principles of use. Am Pharm 1990;NS30:57-63. 46. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-7. 47. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96. 48. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 Suppl 1:1-93. 49. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006;11:32-9. 50. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42. 51. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76. 52. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005;62:247-53. 53. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8. 54. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989;15:81-9. 55. Simpson JC. Mortality studies in schizophrenia. In: Simpson JC, Tsuang MT, eds. Handbook of Schizophrenia, Volume 3: Nosology, Epidemiology and Genetics of Schizophrenia. Amsterdam: Elsevier; 1988:245-74. 56. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53. 57. Ageing DoHa. National Mental Health Report 2005: Summary of Ten Years of Reform in Australia's Mental Health Services Under National Mental Health Strategy 1993-2003. Canberra; 2005. 58. Organization WH. The World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland; 2001. 59. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-8. 60. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31. 61. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42. 62. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. 63. Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-30. 64. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. European Neuropsychopharmacology 2005;15:S526-S. 65. Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68:597-603. 66. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60. 67. Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry 2008;23:561-6. 68. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56. 69. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71. 70. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90. 71. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65 Suppl 18:47-56. 72. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76. 73. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. 74. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52. 75. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80. 76. Almeras N, Despres JP, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65:557-64. 77. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 2008;104:1-12. 78. Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Rev Bras Psiquiatr 2007;29:346-9. 79. Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype. Bipolar Disord 2004;6:314-8. 80. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007;90:162-73. 81. Cerit C, Ozten E, Yildiz M. [The prevalence of metabolic syndrome and related factors in patients with schizophrenia]. Turk Psikiyatri Derg 2008;19:124-32. 82. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60. 83. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67:575-83. 84. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93. 85. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14. 86. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32. 87. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18. 88. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22. 89. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008;22:547-62. 90. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9. 91. Blair SN, Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 1999;31:S646-62. 92. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004;47:S64-6. 93. Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004;65:702-6. 94. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005;66:167-73. 95. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-13. 96. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12. 97. Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004;181:544-8. 98. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31. 99. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol 2005;8:175-82. 100. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-7. 101. Taylor D, Young C, Mohamed R, Paton C, Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-6. 102. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-11. 103. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495. 104. Cheta D, Dumitrescu C, Georgescu M, et al. A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabete Metab 1990;16:11-5. 105. Lamberti J, Crilly J, Maharaj K, Olson D, Costea O. Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs. Schizophrenia Research 2003;60:360-. 106. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007;33:169-75. 107. Scheen AJ, De Hert M. [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics]. Rev Med Liege 2005;60:455-60. 108. McCreadie R, Macdonald E, Blacklock C, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 1998;317:784-5. 109. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701. 110. Hiles BW. HYPERGLYCEMIA AND GLYCOSURIA FOLLOWING CHLORPROMAZINE THERAPY. J Am Med Assoc 1956;162:1651-. 111. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107-16. 112. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-23. 113. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91. 114. Scheen A, De Hert M, Hanssens L, et al. Anomalies de la tolérance au glucose chez les patients schizophrènes traités par antipsychotiques de seconde génération : étude comparative prospective de 3 mois. Diabetes & Metabolism 2007;33:1S129. 115. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61:1356-70. 116. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35. 117. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006;31:2091-120. 118. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472-9. 119. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504-14. 120. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-71. 121. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005;54:1552-8. 122. De Hert M, Hanssens L, van Winkel R, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006;29:2329-30. 123. Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009;70:487-99. 124. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003. 125. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008;117:342-7. 126. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs 2007;21:911-36. 127. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68:1682-90. 128. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192:406-11. 129. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006;8:125-35. 130. Baastrup PC, Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980;6:56-9. 131. Abraham G, Friedman RH, Verghese C, de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry 1995;38:131-2. 132. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996;22:447-54. 133. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94. 134. Delva NJ, Crammer JL, Jarzylo SV, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989;26:781-93. 135. Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002;111:11-20. 136. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001;26:27-35. 137. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204. 138. Durham RA, Johnson JD, Eaton MJ, Moore KE, Lookingland KJ. Opposing roles for dopamine D1 and D2 receptors in the regulation of hypothalamic tuberoinfundibular dopamine neurons. Eur J Pharmacol 1998;355:141-7. 139. Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249-332. 140. Lindsay R, Cosman F. Skeletal effects of estrogen analogs. Osteoporos Int 1997;7 Suppl 1:S40-2. 141. Lindsay R. The effect of sex steroids on the skeleton in premenopausal women. Am J Obstet Gynecol 1992;166:1993-6. 142. Nestoros JN, Lehmann HE, Ban TA. Neuroleptic drugs and sexual function in schizophrenia. Mod Probl Pharmacopsychiatry 1980;15:111-30. 143. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19:603-6. 144. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28 Suppl 2:55-68. 145. Nordstrom AL, Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998;18:305-10. 146. Naber D, Fischer H, Ackenheil M. Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 1979;3:59-65. 147. Chouinard G, Annable L, Jones BD, Collu R. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand 1981;64:353-62. 148. Meltzer HY. Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 1985;40:59-68. 149. Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 1985;40:95-8. 150. Zelaschi NM, Delucchi GA, Rodriguez JL. High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 1996;39:900-1. 151. Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004;116:49-51, 5-9, 63. 152. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39. 153. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425-9. 154. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-5. 155. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-47. 156. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003;64:1362-9. 157. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27:639-61. 158. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61. 159. von Bardeleben U, Benkert O, Holsboer F. Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug. Pharmacopsychiatry 1987;20:28-34. 160. Svestka J, Synek O, Tomanova J, Rodakova I, Cejpkova A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007;28:881-8. 161. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007;21:768-73. 162. Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 2008;22:56-62. 163. Schlosser R, Grunder G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46:33-40. 164. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18. 165. Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J Clin Psychiatry 2003;64:1192-4. 166. Hamner MB, Arvanitis LA, Miller BG, Link CG, Hong WW. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996;32:107-10. 167. Arvanitis LA, Miller BG. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46. 168. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992-7. 169. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-33. 170. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304. 171. Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9:239-45. 172. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005;162:1542-3. 173. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36. 174. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:714-7. 175. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9. 176. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002;112:817-28. 177. Liu-Seifert H, Kinon BJ, Ahl J, Lamberson S. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci 2004;1032:297-8. 178. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25:26-31. 179. Meaney AM, O'Keane V. Bone mi | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45786 | - |
dc.description.abstract | 研究背景 第二代抗精神病藥物因錐體外系統的副作用較少,而且對負向症狀、認知與情緒也有較佳的治療效果,目前已並列為精神分裂症的第一線治療藥物。過去研究發現,精神分裂症患者罹患代謝症候群(例如:糖尿病)和低骨密度的比例較高,除了精神分裂症本身會增加風險之外,使用抗精神病藥物也可能影響代謝症候群的發生和骨質健康,特別是第二代抗精神病藥物對血糖的影響逐漸被關注。目前國內尚無抗精神病藥物影響糖尿病和骨折發生之全國性藥物流行病學研究,本研究的進行,期望能提供臨床醫療人員在用藥選擇上的參考。
研究目的 比較精神分裂症新診斷者與非精神科族群發生糖尿病事件與骨折事件的差異。針對精神分裂症新診斷者,探討其使用第一代和各別第二代抗精神病藥物對於發生糖尿病事件、骨折事件和各部位骨折事件的影響。 研究方法 本研究為一回溯性世代分析,以健保資料庫2005年100萬人承保抽樣歸人檔(LHID2005)為研究材料,針對2001年至2008年間新診斷為精神分裂症的患者為研究對象,再依研究事件篩選糖尿病事件和骨折事件的研究族群,並從LHID2005找出1997年至2008年間無精神科相關診斷者,分別與兩事件研究族群的年齡及性別以1:4比例與進行配對,得到非精神科族群對照組。第一部份比較精神分裂症患者與非精神科族群,在糖尿病事件和骨折事件發生率和發生年齡的差異。第二部分根據是否使用抗精神病藥物將精神分裂症新診斷者分為用藥組和未用藥組,進行背景資料的描述性分析。第三部分以糖尿病事件、骨折事件以及各部位骨折事件為研究終點,利用time-dependent Cox’s proportional hazard model來進行存活分析,探討使用各種抗精神病藥物與用量對於終點事件風險的影響。 研究結果 針對糖尿病事件,符合研究條件的糖尿病事件研究族群(DM-Schizo group)共2649人,非精神科族群之糖尿病事件對照組(DM-Refere group)共9925人,第一部分研究結果,DM-Schizo group糖尿病事件發生率為7.1%,發生時的平均年齡為49.1歲,DM-Refere group發生率為3.7%,平均年齡為55.5歲,兩組間有顯著差異(p<0.0001)。第二部分研究結果,曾使用抗精神病藥物之用藥組共2414人,未用藥組235人,用藥組的年齡主要集中在11-50歲,未用藥組的分布則較為分散;用藥組在進入研究前後鋰鹽的使用率都較高,進入研究後使用valproate和罹患情感性精神病的比率也比較高。第三部分研究結果,校正可能之干擾因子後,在是否使用抗精神病藥物的模式中,第一代抗精神病藥物和amisulpride的hazard ratio (HR)分別為1.44(95% CI=1.06-1.95, p=0.0192)和2.37(95% CI=1.37-4.10, p=0.0020),顯示使用第一代抗精神病藥物或amisulpride都會增加糖尿病發生風險;抗精神病藥物的累積用量模式中,amisulpride、risperidone和ziprasidone的HR分別為1.005、1.002和1.007,顯示使用amisulpride、risperidone和ziprasidone的劑量越高,可能會增加糖尿病發生的風險。針對骨折事件,符合研究條件的骨折事件研究族群(FRA-Schizo group)共2501人,非精神科族群之骨折事件對照組(FRA-Refere group)共9009人,第一部分研究結果,FRA-Schizo group骨折事件發生率為8.0%,FRA-Refere group發生率為4.7 %,兩組間有顯著差異(p<0.0001),但發生事件時的平均年齡則沒有差異。第二部分研究結果,曾使用抗精神病藥物之用藥組共2284人,未用藥組217人,前者的年齡分布主要集中在11-50歲,後者的年齡分布則較為分散;用藥組在進入研究前後鋰鹽和BZD的使用率都較高,進入研究後使用抗憂鬱症和抗癲癇藥物,罹患情感性精神病和帕金森氏症的情況均較高。第三部分研究結果,校正可能之干擾因子後,是否使用抗精神病藥物和累積用量的模式中,均顯示不論使用何種抗精神病藥物都不會影響精神分裂症患者發生全部部位骨折的風險。然而在頸部和軀幹骨折事件的分析,顯示使用ziprasidone會增加頸部和軀幹骨折發生的風險,HR為5.44(95% CI=1.67-17.76, p=0.0051)。下肢骨折事件中,risperidone的使用者發生下肢骨折事件的風險反而比未使用者低,HR為0.58(95% CI=0.34-0.99, p=0.0473)。脊椎骨折事件中,顯示aripiprazole和zotepine的使用量越高,發生脊椎骨折事件的風險越高,兩者HR皆為1.002(95% CI均為1.000-1.003, p=0.0264和0.007)。 結論 精神分裂症新診斷者發生糖尿病和骨折事件的比率都高於其非精神科族群對照組,而且發生糖尿病事件的年齡明顯較低。不論在糖尿病或骨折事件研究族群當中,曾使用和未使用抗精神病藥物的精神分裂症患者,在年齡分布、用藥和疾病等背景資料上都有不同之處,例如用藥組的族群集中在青壯年,未用藥組的族群年齡分布則較為分散。與大部分國外研究不同,本研究結果顯示使用第一代抗精神病藥物和amisulpride的精神分裂症患者有較高發生糖尿病事件的風險;amisulpride、risperidone和ziprasidone的用量越高,風險也越高。全部部位骨折事件的分析中,抗精神病藥物均未達到顯著的影響。只有在各部位骨折事件中顯示,使用ziprasidone者發生頸部和軀幹骨折的風險較高;而aripiprazole和zotepine的用量越高,其發生脊椎骨折的風險可能越高。然而本研究卻發現使用risperidone發生對下肢骨折事有保護的效果。 | zh_TW |
dc.description.abstract | Background: Second-generation antipsychotics (SGAs), have been demonstrated efficacy in the treatment of schizophrenia with fewer extrapyramidal system side effects than first-generation antipsychotics (FGAs), and accordingly have also been approved as the first-line drugs in treating schizophrenia. However, recent studies found that schizophrenic patients have higher risk for diabetes mellitus (DM) and low bone mineral density, it is speculated that in addition to the disease of schizophrenia itself, the use of antipsychotics may also affect the blood sugar control and bone health, especially the second-generation antipsychotics. There is no national study examing the effects of antipsychotics on DM and fracture risks so far in Asia; therefore, we conducted the current study to provide a reference for clinical medical staffs in selecting drugs.
Objectives: To compare the DM and fracture events rate between schizophrenic patients and non-psychiatric population; and to assess the DM and fracture risks between different antipsychotics in patients with newly diagnosed schizophrenia. Methods: This was a retrospective cohort study. We used a subset database (LHID2005) retrieved from National Health Insurance Research Database (NHIRD) to establish a cohort of patients with new onset of schizophrenia from 2001 to 2008, and screening for non-psychiatric population according to DM and fracture study groups. Descriptive analysis. We compared the DM and fracture event rate and age of onset between schizophrenic patients and non-psychiatric population. The DM and fracture study groups were divided into two groups (Schizo-A group and Schizo-N group), according to the exposure of antipsychotics, and then compared the demographic and clinical characteristics between the two groups. Survival analysis. Our study endpoints were DM, fracture at all sites and each part. We used time-dependent Cox’s proportional hazard model to evaluate the hazard ratio (HR) of all FGAs and individual SGAs for each study endpoints. Results: A total of 2649 new onset schizophrenic patients were included in the DM cohort (DM-Schizo group), and 9925 matched non-psychiatric reference were randomly selected (DM-Refere group). The crude DM event rates were 7.1% and 3.7%, and average DM onset ages were 49.1 y/o and 55.5 y/o in DM-Schizo group and DM-Refere group, respectively (p<0.0001). There were 2414 patients in DM-Schizo-A group and 235 in DM-Schizo-N group; DM-Schizo-A group mainly concentrated in 11-50 y/o, but the age distribution of DM-Schizo-N group is more dispersed. Compared with DM-Schizo-N group, patients in DM-Schizo-A group treated with more lithium and valproate, and had higher prevalence of episodic mood disorders. After adjusted with confounding factors, patients exposed to FGAs and amisulpride were more likely to have DM (FGAs HR=1.44; amisulpride HR=2.37). The higher accumulative dose of amisulpride, risperidone and ziprasidone were associated with a higher risk of DM (amisulpride HR=1.005; risperidone HR=1.002; ziprasidone HR=1.007). A total of 2501 new onset schizophrenic patients were included in the fracture cohort (FRA-Schizo group), and 9009 matched non-psychiatric reference were randomly selected (FRA-Refere group). The crude fracture event rates were 8.0% and 4.7 % in FRA-Schizo group and FRA-Refere group, respectively (p<0.0001). There were 2284 patients in FRA-Schizo-A group and 217 in FRA-Schizo-N group; FRA-Schizo-A group mainly concentrated in 11-50 y/o, but the age distribution of FRA-Schizo-N group is more dispersed. Compared with FRA-Schizo-N group, patients in FRA-Schizo-A group treated with more lithium, BZD, anti-depressants and anti-convulsants, and had higher prevalence of episodic mood disorders and Parkinson's disease. After adjusted with confounding factors, patients exposed to any kinds of antipsychotics were not associated with the occurrance of fracture at all sites. However, patients exposed to ziprasidone was associated with a higher risk of neck/trunk fracture (HR=5.44, CI=1.67-17.76, p=0.0051). Risperidone was associated with a lower risk of lower limb fracture (HR=0.58, 95% CI=0.34-0.99, p=0.0473). The higher accumulative dose of aripiprazole and zotepine were associated with a higher risk of vertebral fracture (HR are both 1.002). Conclusions: The DM and fracture events rate are higher in schizophrenic patients than in non-psychiatric population, and the DM onset age was lower in schizophrenic patients. In both DM and fracture study population, there were some demographic and clinical characteristics differences between Schizo-A group and Schizo-N group. Different from previous study, the use of FGAs and amisulpride were found to be associated with significant increased risk of DM in our study; and the higher accumulative dose of amisulpride, risperidone and ziprasidone were also associated with a higher risk of DM. All antipsychotics seem not to be associated with the risk of fracture at all sites, but ziprasidone was associated with a higher risk of neck/trunk fracture, and the accumulative dose of aripiprazole and zotepine were also associated with a higher risk of vertebral fracture. However, risperidone seems to have a protective effect in lower limb fracture in our study. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:46:07Z (GMT). No. of bitstreams: 1 ntu-99-R97451001-1.pdf: 1330920 bytes, checksum: 4b2ebf823e83802d357cf03a80e58d4d (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 謝辭 i
中文摘要 ii Abstract v 目錄 viii 圖目錄 xi 表目錄 xii 第一章 前言 1 第二章 文獻回顧 4 第1節 精神分裂症的流行病學 4 第2節 精神分裂症的病因學 4 2.2.1 基因 4 2.2.2 環境 4 2.2.3 神經傳導物質 5 第3節 精神分裂症的診斷 6 第4節 精神分裂症的臨床表現 8 2.4.1 正向症狀 8 2.4.2 負向症狀 8 2.4.3 認知障礙 8 第5節 精神分裂症的治療 9 2.5.1 藥物治療 9 2.5.2 非藥物治療 10 第6節 精神分裂症的併發症 11 2.6.1 糖尿病 11 2.6.2 骨折 18 第三章 研究目的 23 第四章 研究方法 24 第1節 研究材料 24 4.1.1 台灣地區100萬人健保資料庫承保抽樣歸人檔,LHID2005 24 第2節 精神分裂症新診斷者與非精神科族群的建立 25 4.2.1 研究性質與架構 25 4.2.2 研究對象納入與排除條件 25 第3節 抗精神病藥物與糖尿病事件之相關性 29 4.3.1 研究性質與架構 29 4.3.2 研究對象納入與排除條件 29 4.3.3 研究終點定義 31 4.3.4 研究期間定義 32 4.3.5 研究分組定義 32 4.3.6 研究資料收集 33 4.3.7 統計分析 38 第4節 抗精神病藥物與骨折事件之相關性 40 4.4.1 研究性質與架構 40 4.4.2 研究對象納入與排除條件 40 4.4.3 研究終點定義 42 4.4.4 研究期間定義 44 4.4.5 研究分組定義 44 4.4.6 研究資料收集 45 4.4.7 統計方法 50 第五章 研究結果 52 第1節 精神分裂症新診斷者與非精神科族群的建立 52 第2節 糖尿病事件研究終點 54 5.2.1 糖尿病事件之分組 54 5.2.2 精神分裂症新診斷者與非精神科族群之糖尿病發生率 57 5.2.3 糖尿病事件研究族群之背景資料分析 59 5.2.4 糖尿病事件之用藥及疾病分析 63 5.2.5 糖尿病事件之存活分析 67 第3節 骨折事件研究終點 72 5.3.1 骨折事件之分組 72 5.3.2 精神分裂症新診斷者與非精神科族群之骨折發生率 75 5.3.3 骨折事件研究族群之背景資料分析 77 5.3.4 骨折事件之用藥及疾病分析 81 5.3.5 骨折事件之存活分析 87 5.3.6 骨折事件次族群之存活分析 92 第六章 討論 98 第1節 糖尿病事件研究終點 98 6.1.1 精神分裂症新診斷者與非精神科族群之糖尿病發生率 98 6.1.2 糖尿病事件研究族群之背景資料分析 99 6.1.3 糖尿病事件研究族群之用藥及疾病分析 102 6.1.4 糖尿病事件之存活分析 103 第2節 骨折事件研究終點 107 6.2.1 精神分裂症新診斷者與非精神科族群之骨折發生率 107 6.2.2 骨折事件研究族群之背景資料分析 110 6.2.3 骨折事件研究族群之用藥及疾病分析 112 6.2.4 骨折事件及骨折事件次族群之存活分析 113 第3節 研究限制與優點 118 6.3.1 研究限制 118 6.3.2 研究優點與特色 118 第七章 結論 120 附錄 135 | |
dc.language.iso | zh-TW | |
dc.title | 精神分裂症患者使用抗精神病藥物之糖尿病與骨折風險研究 | zh_TW |
dc.title | The Influence of Antipsychotics on Diabetes Mellitus and Fracture Risks in Schizophrenic Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 高淑芬,李永凌 | |
dc.subject.keyword | 精神分裂症,抗精神病藥物,糖尿病,骨折, | zh_TW |
dc.subject.keyword | schizophrenia,antipsychotics,diabetes mellitus,fracture, | en |
dc.relation.page | 141 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-06 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 1.3 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。